224 related articles for article (PubMed ID: 33602601)
1. Mesenchymal stem cell energy deficit and oxidative stress contribute to osteopenia in the Pah
Dobrowolski SF; Sudano C; Phua YL; Tourkova IL; Spridik K; Goetzman ES; Vockley J; Blair HC
Mol Genet Metab; 2021 Mar; 132(3):173-179. PubMed ID: 33602601
[TBL] [Abstract][Full Text] [Related]
2. A bone mineralization defect in the Pah
Dobrowolski SF; Tourkova IL; Robinson LJ; Secunda C; Spridik K; Blair HC
Mol Genet Metab; 2018 Nov; 125(3):193-199. PubMed ID: 30201326
[TBL] [Abstract][Full Text] [Related]
3. Glutamine energy substrate anaplerosis increases bone density in the Pah
Dobrowolski SF; Phua YL; Tourkova IL; Sudano C; Vockley J; Larrouture QC; Blair HC
JIMD Rep; 2022 Sep; 63(5):446-452. PubMed ID: 36101821
[TBL] [Abstract][Full Text] [Related]
4. Creatine energy substrate increases bone density in the Pah
Dobrowolski SF; Tourkova IL; Larrouture QC; Blair HC
Mol Genet Metab Rep; 2023 Sep; 36():100996. PubMed ID: 37588420
[TBL] [Abstract][Full Text] [Related]
5. A New View of Bone Loss in Phenylketonuria.
Dobrowolski SF; Tourkova IL; Sudano CR; Larrouture QC; Blair HC
Organogenesis; 2021 Oct; 17(3-4):50-55. PubMed ID: 34432558
[TBL] [Abstract][Full Text] [Related]
6. Comparative metabolomics in the Pah
Dobrowolski SF; Phua YL; Sudano C; Spridik K; Zinn PO; Wang Y; Bharathi S; Vockley J; Goetzman E
Mol Genet Metab; 2022 May; 136(1):38-45. PubMed ID: 35367142
[TBL] [Abstract][Full Text] [Related]
7. Phenylketonuria oxidative stress and energy dysregulation: Emerging pathophysiological elements provide interventional opportunity.
Dobrowolski SF; Phua YL; Vockley J; Goetzman E; Blair HC
Mol Genet Metab; 2022 Jun; 136(2):111-117. PubMed ID: 35379539
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation in the pathophysiology of hyperphenylalaninemia in the PAH(enu2) mouse model of phenylketonuria.
Dobrowolski SF; Lyons-Weiler J; Spridik K; Vockley J; Skvorak K; Biery A
Mol Genet Metab; 2016 Sep; 119(1-2):1-7. PubMed ID: 26822703
[TBL] [Abstract][Full Text] [Related]
9. Phenylalanine hydroxylase deficient phenylketonuria comparative metabolomics identifies energy pathway disruption and oxidative stress.
Dobrowolski SF; Phua YL; Sudano C; Spridik K; Zinn PO; Wang Y; Bharathi S; Vockley J; Goetzman E
Mol Genet Metab; 2021 Apr; ():. PubMed ID: 33846068
[TBL] [Abstract][Full Text] [Related]
10. Blood phenylalanine reduction corrects CNS dopamine and serotonin deficiencies and partially improves behavioral performance in adult phenylketonuric mice.
Winn SR; Scherer T; Thöny B; Ying M; Martinez A; Weber S; Raber J; Harding CO
Mol Genet Metab; 2018 Jan; 123(1):6-20. PubMed ID: 29331172
[TBL] [Abstract][Full Text] [Related]
11. Expression of phenylalanine hydroxylase (PAH) in erythrogenic bone marrow does not correct hyperphenylalaninemia in Pah(enu2) mice.
Harding CO; Neff M; Jones K; Wild K; Wolff JA
J Gene Med; 2003 Nov; 5(11):984-93. PubMed ID: 14601136
[TBL] [Abstract][Full Text] [Related]
12. Hepatocytes from wild-type or heterozygous donors are equally effective in achieving successful therapeutic liver repopulation in murine phenylketonuria (PKU).
Hamman KJ; Winn SR; Harding CO
Mol Genet Metab; 2011 Nov; 104(3):235-40. PubMed ID: 21917493
[TBL] [Abstract][Full Text] [Related]
13. Low bone strength is a manifestation of phenylketonuria in mice and is attenuated by a glycomacropeptide diet.
Solverson P; Murali SG; Litscher SJ; Blank RD; Ney DM
PLoS One; 2012; 7(9):e45165. PubMed ID: 23028819
[TBL] [Abstract][Full Text] [Related]
14. Modeling the cognitive effects of diet discontinuation in adults with phenylketonuria (PKU) using pegvaliase therapy in PAH-deficient mice.
Winn SR; Dudley S; Scherer T; Rimann N; Thöny B; Boutros S; Krenik D; Raber J; Harding CO
Mol Genet Metab; 2022 May; 136(1):46-64. PubMed ID: 35339387
[TBL] [Abstract][Full Text] [Related]
15. Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice.
Mochizuki S; Mizukami H; Ogura T; Kure S; Ichinohe A; Kojima K; Matsubara Y; Kobayahi E; Okada T; Hoshika A; Ozawa K; Kume A
Gene Ther; 2004 Jul; 11(13):1081-6. PubMed ID: 15057263
[TBL] [Abstract][Full Text] [Related]
16. Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer.
Oh HJ; Park ES; Kang S; Jo I; Jung SC
Pediatr Res; 2004 Aug; 56(2):278-84. PubMed ID: 15181195
[TBL] [Abstract][Full Text] [Related]
17. PKU is a reversible neurodegenerative process within the nigrostriatum that begins as early as 4 weeks of age in Pah(enu2) mice.
Embury JE; Charron CE; Martynyuk A; Zori AG; Liu B; Ali SF; Rowland NE; Laipis PJ
Brain Res; 2007 Jan; 1127(1):136-50. PubMed ID: 17112485
[TBL] [Abstract][Full Text] [Related]
18. Characterization of 2-(methylamino)alkanoic acid capacity to restrict blood-brain phenylalanine transport in Pah enu2 mice: preliminary findings.
Vogel KR; Arning E; Wasek BL; Bottiglieri T; Gibson KM
Mol Genet Metab; 2013; 110 Suppl(0):S71-8. PubMed ID: 23999161
[TBL] [Abstract][Full Text] [Related]
19. Phenylketonuria: Direct and indirect effects of phenylalanine.
Schlegel G; Scholz R; Ullrich K; Santer R; Rune GM
Exp Neurol; 2016 Jul; 281():28-36. PubMed ID: 27091224
[TBL] [Abstract][Full Text] [Related]
20. In vivo catecholaminergic metabolism in the medial prefrontal cortex of ENU2 mice: an investigation of the cortical dopamine deficit in phenylketonuria.
Pascucci T; Giacovazzo G; Andolina D; Conversi D; Cruciani F; Cabib S; Puglisi-Allegra S
J Inherit Metab Dis; 2012 Nov; 35(6):1001-9. PubMed ID: 22447154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
